Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Bio Medica (ABMC) drug test solution -taking off! -- Ignore unavailable to you. Want to Upgrade?

To: John Anderfuren who wrote (590)	6/14/2000 11:43:00 AM
From: Skywatcher	Respond to of 629

American Bio Medica Wins Decision in Patent Infringement Suit KINDERHOOK, N.Y.--(BUSINESS WIRE)--June 14, 2000--American Bio Medica Corp. (Nasdaq:ABMC - news), which develops, manufactures and markets drugs-of-abuse diagnostic kits, sprays and support services, reported today that it has prevailed in another challenge by Phamatech Inc., of San Diego, Calif., to its design patent. The United States District Court for the Southern District of California ruled that Phamatech's petition for relief was denied and further ruled that Phamatech's attempt to invalidate ABMC's Rapid Drug Screen(TM) patent was denied. Phamatech had filed its declaratory judgment and other claims the day after ABMC had filed suit in Delaware against Phamatech. ABMC's earlier filed case is still pending, and for convenience, it has been assigned to the same Judge that ruled in Phamatech's declaratory judgment case. Phamatech had requested a summary judgment by the court that the design patent claim made by ABMC against Phamatech was invalid and therefore the Phamatech product did not infringe upon ABMC's intellectual property rights. It also asked that the court find Phamatech's trade dress, or overall appearance, did not infringe ABMC's patent, and that the company did not infringe upon ABMC's intellectual property rights. The ABMC claims at issue were identified by the presiding Judge as follows: . . . (1) Patent infringement; (2) violation of section 43(a) of the Lanham Act; (3) violation of 43(c) of the Lanham Act; (4) violation of common law trademark rights; (5) common law unfair competition; (6) violation of California and Business Professions Code ss.ss. 17200 and 17500 et seq.; and (7) violation of California and Business Professions Code ss.ss. 14330 and 14335. Despite Phamatech's contentions, the Court ruled that ABMC's Lanham Act complaints, which Phamatech attacked, were valid claims allowing proceedings to continue in ABMC's trade dress claim and common law infringements. The Court ruled adversely to ABMC on other Lanham Act claims, but those claims did not have the importance to ABMC or Phamatech. The parties' focus was on ABMC's patent claim. Phamatech suffered a defeat of its motion to strike ABMC's multiple assertions of unfair competition by Phamatech. Those claims also will proceed against Phamatech. ``These motions were a distraction to the central patent-infringement case brought by ABMC against Phamatech, a former vendor to ABMC, charging Phamatech with copying and marketing ABMC's Rapid Drug Screen(TM) drug-abuse tests. The principal case now may proceed to the discovery and trial phases,'' stated ABMC Chairman and CEO Stan Cipkowski. Cipkowski added, ``We are extremely pleased and encouraged with this recent decision. We also feel it reflects the strength and validity of our case against Phamatech and other parties for patent infringement, trade dress and unfair competition. We are now looking forward to future proceedings with our request for an injunction and money damages against Phamatech and removal of the copycat products from the market.'' In reaching the decision on patent infringement, the Court had before it expert testimony from each side's patent expert. The Court accepted the opinions and observations made by ABMC's expert. The opinion of Phamatech's expert on what does and does not infringe, was considered and rejected. MAYBE...this thing will start moving here...earnings coming in the next couple weeks. chris

To: John Anderfuren who wrote (590)	6/22/2000 1:24:00 AM
From: Skywatcher	Respond to of 629

American Bio Medica Debuts Its Retail Drug Detector Introduces Spray Test at Chain Drug Stores' Conference KINDERHOOK, N.Y.--(BUSINESS WIRE)--June 21, 2000-- American Bio Medica Corp. (NASDAQ: ABMC - news), which develops, manufactures and markets drugs-of-abuse diagnostic kits, sprays and support services, will introduce its first over-the-counter product at the National Association of Chain Drug Stores Marketplace trade show in New Orleans June 25 - 28. ABMC will demonstrate its wipe-and-spray Drug Detector(TM) that tests for the presence or absence of crack/cocaine or marijuana residue on surfaces, such as desk tops, book bags and steering wheels. The patented Drug Detector kit includes an aerosol spray for either crack/cocaine or marijuana, 10 collection papers and instructions. It's easy to use -- just wipe any surface with a collection paper and spray the paper with the aerosol can. If it detects the drug residue, the paper will turn blue for cocaine and reddish brown for marijuana within seconds. In about two months, ABMC will offer the Drug Detector for methamphetamine and heroine, in addition to the cocaine and marijuana tests, in larger, industrial-size versions of 50-100 tests. ``We are delighted to introduce our first OTC product at this very important gathering of retailers,'' said ABMC chairman and CEO Stan Cipkowski. ``We consider Drug Detector a break-through product for the retail market that will enable parents, spouses and other responsible parties to detect drug use with or without the person's knowledge. This is the market's first, completely reliable, arms-length drug test for the most commonly abused drugs.'' ABMC has a second product ready for retail release pending FDA approval of over-the-counter sales: Rapid Drug Screen(TM) on-site tests that generate results in five minutes and are unrivaled in the market for ease of use. Each test kit includes a plastic cup with an affixed temperature strip and secure lid for a urine sample. One or more Rapid Drug Screen test cards are inserted into the urine through a safety-sealed slit in the cup lid and, in minutes, indicate the presence or absence of the drugs covered by the cards: cocaine, opiates, marijuana, PCP, barbituates, benzodiazepines, tricyclic antidepressants, methamphetamine, amphetamines and methadone individually or in various combinations. Rapid Drug Screens are already in use at the institutional level by clinicians, educators, government, judiciary and business customers, and are proven to correlate 100% with the standard laboratory test. More than 1,000 companies are expected to be represented at the Chain Drug Stores Marketplace this year. This will be the first time ABMC has participated in the show and its representatives look forward to meeting visitors at booth #1682 chris

To: John Anderfuren who wrote (590)	7/12/2000 2:20:46 AM
From: Skywatcher	Read Replies (2) \| Respond to of 629

American Bio Medica Plans Major Sales Drive in Latin America, Names Former Roche Consultant as Sales Director KINDERHOOK, N.Y.--(BUSINESS WIRE)--July 11, 2000--American Bio Medica Corp. (NASDAQ:ABMC - news), which develops, manufactures and markets drugs-of-abuse diagnostic kits, sprays and support services, today announced that Arthur E. Brodeur, a former Roche Diagnostics consultant, has joined the company as director of sales for Mexico and Latin America and will manage a major sales effort in the region. Brodeur has more than 25 years of experience in sales and marketing, most recently with Roche Diagnostics' Drugs-of-Abuse Business Unit where he was a sales and marketing consultant responsible for coordinating marketing for Roche affiliates in Latin America and Canada. He also was responsible for identifying global distributors for Roche Diagnostics' drug-of-abuse products. Previously, Brodeur was with Bio-Merieux/API for 20 years, beginning as a sales rep and rising to vice president of sales. ``Art is our first sales director exclusively for Mexico and Latin America, and we are very fortunate to have such a highly qualified individual take on this assignment. His skills and experience are an excellent match for our aggressive marketing strategy,'' said ABMC Chairman and CEO Stan Cipkowski. That strategy includes Rapid Drug Screen(TM), on-site urine tests that generate results in five minutes and are unrivaled for ease of use, and Drug Detector(TM), the wipe-and-spray, non-invasive drug detection kit introduced last week at the Association of Chain Drug Stores' Marketplace trade show in New Orleans. Rapid Drug Screen is already in use at the institutional level by clinicians, educators, government, judiciary and business customers, and is awaiting FDA approval for retail distribution. Each test kit includes a plastic cup with an affixed temperature strip and secure lid for a urine sample. One or more Rapid Drug Screen test cards are inserted into the urine through a safety-sealed slit in the cup lid and, in minutes, indicate the presence or absence of the drugs covered by the test cards: cocaine, opiates, marijuana, PCP, barbiturates, benzodiazepines, tricyclic antidepressants, methamphetamine, amphetamines and methadone, individually or in various combinations. Drug Detector, was introduced first to the U.S. retail market in tests for marijuana and crack/cocaine. The test kit includes an aerosol spray for either crack/cocaine or marijuana, 10 collection papers and instructions. It's easy to use -- just wipe any surface with a collection paper and spray the paper with the aerosol can. If it detects the drug residue, within seconds the paper will turn blue for cocaine and reddish brown for marijuana. Drug Detector will be available to the Mexican and Latin American institutional markets in larger, industrial-size versions of 50-100 tests. Tests for methamphetamine and heroin will be added at a later date. Both Drug Detector and Rapid Drug Screen will figure prominently in ABMC's plans for Mexico and Latin America, where Cipkowski and Brodeur see an untapped market of great potential. American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs-of-abuse diagnostic kits, sprays and supports services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. chris